A detailed history of Pdt Partners, LLC transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Pdt Partners, LLC holds 139,296 shares of AKRO stock, worth $4.27 Million. This represents 0.39% of its overall portfolio holdings.

Number of Shares
139,296
Previous 139,296 -0.0%
Holding current value
$4.27 Million
Previous $3.27 Million 22.31%
% of portfolio
0.39%
Previous 0.33%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 15, 2024

BUY
$18.31 - $24.62 $271,866 - $365,557
14,848 Added 11.93%
139,296 $3.27 Million
Q1 2024

May 15, 2024

BUY
$17.76 - $31.18 $2.21 Million - $3.88 Million
124,448 New
124,448 $3.14 Million
Q3 2022

Nov 14, 2022

SELL
$10.15 - $34.05 $144,931 - $486,199
-14,279 Reduced 36.73%
24,593 $837,000
Q2 2022

Aug 15, 2022

BUY
$8.0 - $15.01 $310,976 - $583,468
38,872 New
38,872 $367,000

Others Institutions Holding AKRO

About Akero Therapeutics, Inc.


  • Ticker AKRO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,417,600
  • Market Cap $1.42B
  • Description
  • Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...
More about AKRO
Track This Portfolio

Track Pdt Partners, LLC Portfolio

Follow Pdt Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pdt Partners, LLC with notifications on news.